<?xml version='1.0' encoding='utf-8'?>
<document id="27042423"><sentence text="Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence."><entity charOffset="0-14" id="DDI-PubMed.27042423.s1.e0" text="Sodium-glucose" /></sentence><sentence text="As type 2 diabetes mellitus (T2DM) is a chronic and progressive disease with multiple pathophysiologic defects, no single anti-diabetic agent can tackle all these multi-factorial pathways" /><sentence text=" Consequently, multiple agents working through the different mechanisms will be required for the optimal glycemic control" /><sentence text=" Moreover, the combination therapies of different anti-diabetic agents may complement their actions and possibly act synergistic" /><sentence text=" Furthermore, these combinations could possess the additional properties to counter their undesired physiological compensatory response" /><sentence text=" Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are newly emerging class of drugs, with a great potential to reduce glucose effectively with an additional quality of lowering cardiovascular events as demonstrated very recently by one of the agents of this class"><entity charOffset="1-15" id="DDI-PubMed.27042423.s6.e0" text="Sodium-glucose" /><entity charOffset="122-129" id="DDI-PubMed.27042423.s6.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.27042423.s6.e0" e2="DDI-PubMed.27042423.s6.e0" /><pair ddi="false" e1="DDI-PubMed.27042423.s6.e0" e2="DDI-PubMed.27042423.s6.e1" /></sentence><sentence text=" However, increase in endogenous glucose production (EGP) from the liver, either due to the increase in glucagon or compensatory response to glucosuria can offset the glucose-lowering potential of SGLT-2I"><entity charOffset="33-40" id="DDI-PubMed.27042423.s7.e0" text="glucose" /><entity charOffset="167-174" id="DDI-PubMed.27042423.s7.e1" text="glucose" /><pair ddi="false" e1="DDI-PubMed.27042423.s7.e0" e2="DDI-PubMed.27042423.s7.e0" /><pair ddi="false" e1="DDI-PubMed.27042423.s7.e0" e2="DDI-PubMed.27042423.s7.e1" /></sentence><sentence text=" Interestingly, another class of drugs such as dipeptidyl peptidase-4 inhibitors (DPP-4I) effectively decrease glucagon and reduce EGP" /><sentence text=" In light of these findings, combination therapies with SGLT-2I and DPP-4I are particularly appealing and are expected to produce a synergistic effect" /><sentence text=" Preclinical studies of combination therapies with DPP-4I and SGLT-2I have already demonstrated a significant lowering of hemoglobin A1c potential and human studies also find no drug-drug interaction between these agents" /><sentence text=" This article aims to systematically review the efficacy and safety of combination therapy of SGLT-2I and DPP-4I in T2DM" /><sentence text=" " /></document>